Status:
COMPLETED
A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects
Lead Sponsor:
PowderMed
Conditions:
HSV-2
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing. The study will also test the abi...
Detailed Description
Herpes simplex virus type 2 (HSV-2) infection is a serious public health problem, with up to 20% of the US population infected. Following primary infection, HSV-2 establishes a latent infection that c...
Eligibility Criteria
Inclusion
- Otherwise healthy subjects with seronegative HSV-2
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00310271
Start Date
April 1 2006
End Date
December 1 2006
Last Update
November 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CPC Phase I Unit
Lenexa, Kansas, United States, 66219